Medpace Holdings, Inc. (MEDP) Q3 Revenue Up 8.5%, EPS $4.84; Launches $1B Buyback

Medpace (MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and GAAP EPS of $4.84. Backlog increased to $3.17B, and the company launched a $1B buyback program. 2026 guidance was reaffirmed at $2.835B–$2.855B revenue and GAAP net income of $514M–$524M.

Original reporting
Published Oct 21, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medpace Holdings, Inc. (MEDP) Q3 Revenue Up 8.5%, EPS $4.84; Launches $1B Buyback — source image
Decision brief

The 30-second read

$MEDPBullishMed
01

Why it matters

The combination of a reported Q3 beat-style datapoint (revenue growth and EPS), higher backlog ($3.17B), reaffirmed 2026 guidance, and a new $1.0B repurchase authorization creates multiple near-term valuation supports.

02

Market read

Traders can reassess near-term expectations for CRO demand and capital return based on the fresh quarterly results and the newly authorized repurchase.

03

What to watch

The article does not quantify buyback timing, execution pace, or any margin commentary, so traders may need to verify whether EPS quality and cash flow back the buyback capacity.

Relevance 9/10Novelty 8/10Timing: after-hours/overnight following the Q3 results release

Background

Medpace is a CRO, and the article frames the quarter as continuation of multi-year growth and margin expansion, with backlog supporting 2026 targets.

Company-level read

Ticker impact

$MEDPBullishHigh confidence
Context

Medpace reported Q3 2026 revenue of $716.0M (+8.5% YoY) and GAAP EPS of $4.84, alongside a new $1.0B buyback authorization.

Expected impact

Likely upward bias as investors price in sustained CRO demand plus increased buyback support.

Evidence & confidence

The article discloses a fresh quarterly print (revenue, EPS), reaffirmed 2026 guidance, and a new, sizable repurchase authorization, all of which are direct valuation catalysts.

Market effects

Reinforces the CRO growth and margin-expansion narrative, potentially improving sentiment toward other contract research organizations.

Primarily US large-cap sentiment; limited direct regional spillover beyond healthcare services.

Modest, as CRO demand is globally driven but the disclosed catalysts are company-specific.

Counterpoint

Buyback enthusiasm may be partially offset if backlog conversion or book-to-bill weakens, making the guidance reaffirmation less durable than the headline suggests.

Key entities

  • Medpace Holdings, Inc.

    Reported Q3 2026 revenue $716.0M (+8.5% YoY), GAAP EPS $4.84, backlog $3.17B, reaffirmed 2026 guidance, and approved up to $1.0B buyback.

Related articles

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.